{"DataElement":{"publicId":"5270314","version":"1","preferredName":"Patient Histologically Confirmation Retinoblastoma-Associated Protein Positive Finding Central Nervous System Disease or Disorder Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The yes/no/not applicable response regarding whether a patient with a central nervous system tumor has histologically confirmed Rb1 positive finding that meets the criteria to participate in a clinical trial.","longName":"HIS_RB_POS_CNS_DS_EC","context":"PBTC","contextVersion":"1","DataElementConcept":{"publicId":"5270313","version":"1","preferredName":"Patient Histologically Confirmation Retinoblastoma-Associated Protein Positive Finding Central Nervous System Disease or Disorder Clinical Trial Eligibility Criteria","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Involving the use of histology or histological techniques._Having been established or verified._Retinoblastoma-associated protein (928 aa, ~106 kDa) is encoded by the human RB1 gene. This protein plays a role in the regulation of cell cycle progression._A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism._The part of the nervous system that consists of the brain, spinal cord, and meninges._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2233604v1.0:5270311v1.0","context":"PBTC","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5270311","version":"1","preferredName":"Histologically Confirmation Retinoblastoma-Associated Protein Positive Finding Central Nervous System Disease or Disorder Clinical Trial Eligibility Criteria","preferredDefinition":"Involving the use of histology or histological techniques.:Having been established or verified.:Retinoblastoma-associated protein (928 aa, ~106 kDa) is encoded by the human RB1 gene. This protein plays a role in the regulation of cell cycle progression.:A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.:The part of the nervous system that consists of the brain, spinal cord, and meninges.:Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"5270311v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histologically","conceptCode":"C25527","definition":"Involving the use of histology or histological techniques.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Confirmation","conceptCode":"C25458","definition":"Having been established or verified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Retinoblastoma-Associated Protein","conceptCode":"C17394","definition":"Retinoblastoma-associated protein (928 aa, ~106 kDa) is encoded by the human RB1 gene. This protein plays a role in the regulation of cell cycle progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Positive Finding","conceptCode":"C38758","definition":"A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Central Nervous System","conceptCode":"C12438","definition":"The part of the nervous system that consists of the brain, spinal cord, and meninges.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"33113AFC-AB5A-E939-E050-BB89AD4351B0","latestVersionIndicator":"Yes","beginDate":"2016-05-17","endDate":null,"createdBy":"SWEW","dateCreated":"2016-05-17","modifiedBy":"ONEDATA","dateModified":"2016-05-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"33113AFC-AB6B-E939-E050-BB89AD4351B0","latestVersionIndicator":"Yes","beginDate":"2016-05-17","endDate":null,"createdBy":"SWEW","dateCreated":"2016-05-17","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"PBTC_WMS_051716","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506036","version":"1","preferredName":"Yes No Not Applicable Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.","longName":"YES_NO_NA_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"14","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Not Applicable","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"3261243","version":"1","preferredName":"Not Applicable","longName":"3261243","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA2BBD66-6581-A6F2-E040-BB89AD4311D3","latestVersionIndicator":"Yes","beginDate":"2011-08-10","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-10","modifiedBy":"RAGUNATHANU","dateModified":"2024-02-05","changeDescription":"12/15/15 added N/A as alternate VM-tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-759A-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75A4-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-7590-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2694966","version":"1","preferredName":"Ind-3b","preferredDefinition":"A response or indicator that can have a value of yes, no, or not applicable.","longName":"C49797","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes, No, or Not Applicable Response","conceptCode":"C49797","definition":"A response or indicator that can have a value of yes, no, or not applicable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"3EBCA780-282F-4411-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-11-12","endDate":"2016-04-27","createdBy":"CURTIST","dateCreated":"2007-11-12","modifiedBy":"TAYLORT","dateModified":"2020-10-02","changeDescription":"10.2.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Retired DBW 04-27-2016 per Tina Taylor approved by Dianne Reves","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-757C-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ZHANGWE","dateModified":"2019-01-24","changeDescription":"3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. 8/3/2015 Corrections made to VD in order to restore to original format: removed C49486 as rep term and replaced with C49797; restored long name and definition per Dianne Reeves/tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4254096","version":"1","longName":"Protocol Phase","context":"PBTC","ClassificationSchemeItems":[{"publicId":"10000103","version":"1","longName":"Phase I","context":"PBTC"},{"publicId":"4254119","version":"1","longName":"PBTC-042","context":"PBTC"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"PBTC_Text1","type":"Alternate Question Text","description":"Does patient have a histologically confirmed Rb1 positive recurrent, progressive or refractory central nervous system tumor (excluding low-grade gliomas)?","url":null,"context":"PBTC"},{"name":"Does patient have a histologi","type":"Preferred Question Text","description":"Does patient have a histologically confirmed Rb1 positive central nervous system tumor?","url":null,"context":"PBTC"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"331184B9-95AF-D09A-E050-BB89AD432444","latestVersionIndicator":"Yes","beginDate":"2016-05-17","endDate":null,"createdBy":"SWEW","dateCreated":"2016-05-17","modifiedBy":"SWEW","dateModified":"2016-05-19","changeDescription":"PBTC_WMS_051716","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}